{"doi":"10.2217/fon-2022-1249","title":"SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR\n            <i>BRAF</i>\n            V600E-mutant mCRC","abstract":null,"journal":"Future Oncology","year":2024,"id":609146,"datarank":0.5606504427425053,"base_score":3.7376696182833684,"endowment":3.7376696182833684,"self_citation_contribution":0.5606504427425053,"citation_network_contribution":0.0,"self_endowment_contribution":0.5606504427425053,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":41,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":241627,"name":"Scott Kopetz","orcid":"0000-0001-9647-3416","position":1,"is_corresponding":false},{"id":35283,"name":"Josep Tabernero","orcid":"0000-0002-2495-8139","position":2,"is_corresponding":false},{"id":1413884,"name":"Tanios Bekaii-Saab","orcid":null,"position":3,"is_corresponding":false},{"id":1565531,"name":"Julien Taieb","orcid":null,"position":4,"is_corresponding":false},{"id":310797,"name":"Takayuki Yoshino","orcid":"0000-0002-0489-4756","position":5,"is_corresponding":false},{"id":1565532,"name":"Gulam Manji","orcid":null,"position":6,"is_corresponding":false},{"id":1565533,"name":"Kathrine Fernandez","orcid":null,"position":7,"is_corresponding":false},{"id":1565534,"name":"Antonello Abbattista","orcid":null,"position":8,"is_corresponding":false},{"id":1361013,"name":"Xiaosong Zhang","orcid":"0000-0002-0122-2356","position":9,"is_corresponding":false},{"id":1565535,"name":"Van K Morris","orcid":null,"position":10,"is_corresponding":false},{"id":1565530,"name":"Elena Elez","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR\n            <i>BRAF</i>\n            V600E-mutant mCRC","abstract":"Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC.","is_dataset_classified":null,"base_score":3.7376696182833684,"endowment":3.7376696182833684,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37815847","pmcid":"PMC12510239","openalex_id":"https://openalex.org/W4387473002","authors":[],"funders":[{"funder_name":"NCATS NIH HHS","grant_id":"KL2 TR000370","title":null},{"funder_name":"Funded by Pfizer","grant_id":"","title":null},{"funder_name":"Funded by Pfizer","grant_id":"","title":null}],"total_grants":3,"fwci":4.7814,"citation_percentile":0.96509879,"influential_citations":0,"citation_trend":[{"year":2024,"count":8},{"year":2025,"count":24},{"year":2026,"count":9}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.2217/fon-2022-1249","host_type":"journal"},{"url":"https://doi.org/10.2217/fon-2022-1249","host_type":"publisher"},{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon-2022-1249","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37815847","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12510239","host_type":"repository"},{"url":"https://digitalcommons.library.tmc.edu/uthgsbs_docs/6016","host_type":"repository"},{"url":"https://ddd.uab.cat/record/326606","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12510239/pdf/IFON_20_12367166.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12510239","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12510239?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Colorectal Cancer Treatments and Studies","Genetic factors in colorectal cancer","Lung Cancer Treatments and Mutations","Humans","Cetuximab","Proto-Oncogene Proteins B-raf","Mutation","Colorectal Neoplasms","Colonic Neoplasms","Clinical Trials, Phase II as Topic","Randomized Controlled Trials as Topic","Antibodies, Monoclonal, Humanized","Neoplastic Syndromes, Hereditary","Sulfonamides","Brain Neoplasms","Carbamates","Turcot syndrome"],"mesh_terms":["Cetuximab","Brain Neoplasms","Carbamates","Colonic Neoplasms","Humans","Mutation","Neoplastic Syndromes, Hereditary","Sulfonamides","Colorectal Neoplasms","Randomized Controlled Trials as Topic","Clinical Trials, Phase II as Topic","Proto-Oncogene Proteins B-raf","Antibodies, Monoclonal, Humanized"],"keywords":["Cetuximab","Pembrolizumab","Colorectal cancer","Cancer research","Medicine","Cancer","V600E","DNA mismatch repair","Mutation","Oncology","Internal medicine","Immunotherapy","Gene","Biology","Genetics","Targeted Therapy","Metastatic Colorectal Cancer","Msi-h","Dmmr","Braf V600","Encorafenib","Triplet Combination Therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Life below water"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-31T03:51:25.075600Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}